Stefan D. Anker is Head of Field “Tissue Homeostasis and Cachexia" at Charité University, Berlin, Germany. Previously, he was Professor of Innovative Clinical Trials at University Medical Center Göttingen in Germany. The main focus of the Innovative Clinical Trials department was research in the field of chronic heart failure, including the development and clinical testing of new therapies.He studied medicine at Charité Medical School of Humboldt-University Berlin, Germany (1987-1993) and completed his PhD at the National Heart and Lung Institute of Imperial College London, United Kingdom, in 1998. Since then, he has had teaching appointments in several countries (UK, Germany, Australia, Italy).His particular research interests include the pathophysiology and treatment of acute and chronic heart failure (CHF), cardiac device therapy, clinical evaluation of cardiovascular biomarkers, pathophysiology of muscle wasting, cachexia therapy in CHF, ageing, sarcopenia and cancer.Anker is a member of and serves on the Boards of several academic organisations. He serves on the editorial boards of five scientific journals (including European Heart Journal and European Journal of Heart Failure). He is founding Editor-in-Chief of the Journal of Cachexia, Sarcopenia and Muscle and of ESC Heart Failure, which is the first open access heart failure journal.Anker has won several prizes (including two American Heart Association Young Investigator Awards), and has obtained a number of fellowships and grants, including two National Institutes of Health (NIH) grants (Warfarin Versus Aspirin in Reduced Cardiac Ejection Fraction (WARCEF) Trial), two grants from the EU's Seventh Framework Programme for Research (FP7), and one Innovative Medicines Initiative / Horizon 2020 grant. Source: Wikipedia (en)